Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

1. 12 to 80 years of age, male and female, BMI <40 kg/m2; females must be not ofhildbearing potential or using a form of highly effective birth control.
2. Documented history of physician-diagnosed asthma > and/or = 1 year prior to V1.
3. Regularly using a stable daily ICS/LABA regimen (including a stable ICS dose) withdium-to-high ICS doses for at least 4 weeks prior to V1.
4. ACQ-7 total score ≥1.5 at Visits 1, 3, and 5 (pre-randomization).
5. FEV1 % (assessed as an average of the 60 and 30 minute pre-dose assessments) predictedV1, 2, 3, 4, and 5 (pre-randomization)
   • Participants > and/or = 18 years of age: < 80%
   • Participants 12 to <18 years of age: < 90%
6. FEV1 post-albuterol at V2 or V3 (if repeat needed).
   • Participants > and/or = 18 years of age: Increase > and/or = 12% and > and/or =200 mL.
   • Participants 12 to <18 years of age: Increase =12% either in the 12 months priorVisit 1 or at Visit 2, or at Visit 3.
   • Note: Reversibility testing is still required at Visit 2 and/or Visit 3, even ifhe patient has documented historical reversibility reported in the 12 monthsVisit 1.
7. Willing and, in the opinion of the Investigator, able to adjust current asthma
   therapy, as required by the protocol.
8. Demonstrate acceptable MDI/pMDI administration technique.
9. Received no asthma medication other than run-in BFF MDI BID and albuterol as neededduring screening (except for allowed medications as defined in Table 9 and systemicd or ICS for the treatment of an asthma exacerbation).
10. eDiary 14-day compliance ≥70% during screening (defined as completing the daily eDiaryy 10 mornings and any 10 evenings and answering "Yes" to taking 2 puffs ofun-in BFF MDI for any 10 mornings and 10 evenings in the last 14 days prior todomization).
11. No respiratory infection in the 4 weeks prior to randomization, or asthma exacerbationd with systemic corticosteroid and/or additional ICS treatment in the 4 weeksdomization.

1. Completed treatment for respiratory infection or asthma exacerbation with systemicds within 4 weeks of V1.

2a. Participants where, in the opinion of the Investigator, treatment with biological
    therapy for asthma would be appropriate.
    2b. Any marketed or investigational biologics within 3 months or 5 half-lives of V1,
    whichever is longer and must not be used during study duration.
    3. Current smokers, former smokers with >10 pack-years history, or former smokers who
    stopped smoking <6 months prior to V1 (including all forms of tobacco, e-cigarettes or
    other vaping devices, and marijuana).
    4. Current evidence of Chronic Obstructive Pulmonary Disease (COPD).
    5a. Oral and IV corticosteroid use (any dose) within 4 weeks of V1.
    5b. Use of systemic corticosteroids for any other reason except for the acute treatment of
    severe asthma exacerbation is prohibited for the duration of the study.
    5c. Depot corticosteroid use for any reason within 12 months of V1.
    6. Use of Long-Acting Muscarinic Antagonist (LAMA), either alone or as part of an inhaled
    combination therapy, in the 12 weeks prior to V1.
    7. Use of oral b2-agonist within 3 months of V1.
    8. Use of any immunomodulators or immunosuppressive medication within 3 months or 5
    half-lives, whichever is longer, and must not be used during the study duration.
    9. Narrow angle glaucoma not adequately treated and/or change in vision that may be
    relevant, in the opinion of the Investigator, within 3 months of Visit 1.
    10. Life-threatening asthma defined as a history of significant asthma episode(s) requiring
    intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or
    asthma-related syncopal episode(s).
    11. Hospitalization for asthma within 2 months of Visit 1.
    12. Known history of drug or alcohol abuse within 12 months of Visit 1.
    13. Regular use of a nebulizer or a home nebulizer for receiving asthma medications.
    14. Using any herbal products by inhalation or nebulizer within 4 weeks of Visit 1 and does
    not agree to stop during the study duration.
    15. Participation in another clinical study with an Investigational Product.
    16. Participants with a known hypersensitivity to beta2-agonists, corticosteroids,
    anticholinergics, or any component of the MDI or pMDI.
    17. Study Investigators, sub-Investigators, coordinators, and their employees or immediate
    family members.
    18. For women only - currently pregnant (confirmed with positive highly sensitive pregnancy
    test), breast-feeding, or planned pregnancy during the study or not using acceptable
    contraception measures, as judged by the Investigator.
    Please refer to the study protocol for the complete inclusion and exclusion criteria list.